Phuturdex › Diseases › Fatty liver disease
Drugs in development · updated 30 October 2026
Fatty liver disease: drugs in development
As of 30 October 2026 there are 22 active clinical trials (recruiting or ongoing, phases I–III) on 23 drugs for fatty liver disease. 14 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Efimosfermin alfa | III | 2 | NCT07701993 |
| Pegozafermin | III | 2 | NCT06419374 |
| Hydrochloroquine | III | 1 | NCT07265297 |
| Retatrutide | III | 1 | NCT07165028 |
| AZD6234 | I–II | 1 | NCT06151964 |
| AZD9550 | I–II | 1 | NCT06151964 |
| Coenzyme Q10CoQ10 | II | 1 | NCT05984745 |
| Erdosteine | I–II | 1 | NCT07242222 |
| GSK4532990 | II | 1 | NCT06613698 |
| HP515 | II | 1 | NCT07308548 |
| NicotinamideNicotinomide | II | 1 | NCT06599918 |
| [1-13C] sodium acetate | I | 1 | NCT06354088 |
| HRS-4729 | I | 1 | NCT07807059 |
| NNC0581-0001 | I | 1 | NCT06891365 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Obeticholic AcidOcaliva®, Zektayos - Hepjuvo® | III | 2 | NCT06691412 |
| TirzepatideZepbound, Mounjaro | III | 1 | NCT07165028 |
| AtezolizumabTecentriq, MPDL3280A | II | 1 | NCT06096779 |
| Bevacizumabavastin, MVASI | II | 1 | NCT06096779 |
| CilostazolPletal® | I–II | 1 | NCT07238985 |
| SemaglutideWegovy, Rybelsus | II | 1 | NCT03884075 |
| TesamorelinEgrifta® | II | 1 | NCT07481734 |
| AlirocumabPraluent® | I | 1 | NCT04781322 |
| AlpelisibBYL719, Vijoice® | I | 1 | NCT06354088 |
Sorted by most advanced phase and number of active trials.
All 23 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Non-alcoholic Fatty Liver Disease 68 drugs
- Type 2 diabetes 171 drugs
- Liver cirrhosis 38 drugs
- Fibrosis 52 drugs
- Prediabetes 18 drugs
- Obesity 233 drugs
- Diabetes 91 drugs
- Insulin resistance 41 drugs
- Hyperinsulinism 14 drugs
- Hyperlipidemia 26 drugs
- Dyslipidemia 35 drugs
- Hypertriglyceridemia 18 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Liver disease 33 drugs
- Nutritional and metabolic diseases 5 drugs
- Overnutrition 5 drugs
- Nutrition disorder 10 drugs
- Human body weight 13 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005234 “Fatty Liver”.